登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式(希尔记法):
C21H38N4O8 · HCl · xH2O
化学文摘社编号:
分子量:
511.01 (anhydrous basis)
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
12352202
MDL number:
Beilstein/REAXYS Number:
8888370
产品名称
Amastatin hydrochloride hydrate, ≥97% (HPLC)
InChI
1S/C21H38N4O8.ClH.H2O/c1-9(2)7-12(22)17(28)20(31)25-16(11(5)6)19(30)24-15(10(3)4)18(29)23-13(21(32)33)8-14(26)27;;/h9-13,15-17,28H,7-8,22H2,1-6H3,(H,23,29)(H,24,30)(H,25,31)(H,26,27)(H,32,33);1H;1H2/t12-,13+,15+,16+,17+;;/m1../s1
SMILES string
Cl[H].[H]O[H].CC(C)C[C@@H](N)[C@H](O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O
InChI key
WBYDQJQQTMJMQH-AFROIDPFSA-N
biological source
synthetic (organic)
assay
≥97% (HPLC)
form
powder
mp
202-205 °C
solubility
methanol: 1 mM (Stock solution stable for 1 month at −20 °C. Working solution stable for 1 day.)
antibiotic activity spectrum
neoplastics
mode of action
enzyme | inhibits
storage temp.
−20°C
Quality Level
正在寻找类似产品? 访问 产品对比指南
Biochem/physiol Actions
Amastatin is a slow, tight-binding inhibitor of aminopeptidases. It inhibits cytosolic leucine aminopeptidase (EC.3.4.11.1), microsomal aminopeptidase M (EC.3.4.11.2) and bacterial leucine aminopeptidase (EC.3.4.11.10). It is less effective against aminopeptidase A (EC 3.4.11.7), the enzyme that converts Angiotensin II to Angiotensin III. Effective concentration: 1-10 μM.
It inhibits cytosolic leucine aminopeptidase (EC.3.4.11.1), microsomal aminopeptidase M (EC.3.4.11.2) and bacterial leucine aminopeptidase (EC.3.4.11.10). It is less effective against aminopeptidase A (EC 3.4.11.7), the enzyme that converts angiotensin II to angiotensin III. Potentiates the CNS effects of vasopressin and oxytocin in vivo.
Effective concentration: 1-10 μM.
Effective concentration: 1-10 μM.
General description
Chemical structure: peptide
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Gloves, type N95 (US)
Zollner, H.
Handbook of Enzyme Inhibitors, 2nd Ed., 547-547 (1993)
Beynon, R.J. and Bond, J.S.
Proteolytic Enzymes: A Practical Approach, 247-247 (1989)
Yu Wang et al.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 35(3), e21419-e21419 (2021-02-11)
In the early phase of the Coronavirus disease 2019 (COVID-19) pandemic, it was postulated that the renin-angiotensin-system inhibitors (RASi) increase the infection risk. This was primarily based on numerous reports, which stated that the RASi could increase the organ Angiotensin-converting
我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持